DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/52z5js/the_pharmaceutical) has announced the addition of the "The Pharmaceutical Market: Portugal" report to their offering.
In-Depth Information, Setting The Pharmaceutical Market In Context
The report provides:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
MARKET OVERVIEW
The macroenvironment remains tough. Politically, the Prime Minister aims to create a more efficient state and comply with the bail-out commitments signed by the previous socialist government. The austerity programme is expected to remain high on his agenda. Economically, the Economist Intelligence Unit (EIU) believes that economic and fiscal policy will be shaped by the bail-out agreement signed with the EU and the IMF. There are signs that public hospitals will be affected as part of the country's effort to reduce its budget deficit. Legally, IPR regulations are harmonised with EU procedures. Demographically, Portugal has one of the smallest populations in Western Europe, but the EIU projects that the number of people aged 65 years and over will increase to represent nearly one-fifth of the total population in 2017, equal to 2.0 million people.
The Portuguese pharmaceutical market is small but more than doubled in US dollar terms between 1995 and 2011. Market growth in US dollar terms has been affected by exchange rate fluctuations and the economic environment. The market experienced a decline between 2009 and 2011, affected by the economic downturn. A major concern to both the government and the pharmaceutical industry is the sizeable debt owed by the Ministry of Health to companies operating in the hospital sector. In euro terms, pharmaceutical sales are projected to increase modestly in the forecast period, due to the government's cost-containment measures. In 2017, the pharmaceutical market will rank as one of the smallest in Western Europe, ranking 12th. In per capita terms, Portugal will have the lowest expenditure.
Local producers are small and need to merge or form alliances to compete at global level. They also need to invest more in innovation and increase their competitiveness.
ABOUT THIS REPORT
Key Topics Covered:
- Healthcare Statistics
- Executive Summary
- Macroenvironment
- Epidemiology
- Healthcare
- Regulatory Affairs
- Pricing & Reimbursement
- Distribution Channels
- Market Analysis
- Competition
- Otc Pharmaceuticals
- Generic Pharmaceuticals
- Biologics & Biosimilars
- Opportunities & Challenges
- Directory
- Methodology & Sources
Companies Mentioned Include:
- Bial
- Bluepharma
- Hikma Farmac?utica Portugal
- Hovione
- Jaba
- Medinfar
- Labotorios Vit?ria
- Pharmout
- Apifarma
- Apogen
For more information visit http://www.researchandmarkets.com/research/52z5js/the_pharmaceutical